Literature DB >> 17382520

Effects of subinhibitory concentrations of amikacin and ciprofloxacin on the hydrophobicity and adherence to epithelial cells of uropathogenic Escherichia coli strains.

Dorota Wojnicz1, Stanislaw Jankowski.   

Abstract

The effect of subinhibitory concentrations of amikacin and ciprofloxacin on the hydrophobicity and adherence to uroepithelial cells of Escherichia coli strains was investigated. The hydrophobicity of the tested strains was evaluated by the bacterial adherence to hydrocarbon-xylene test and by the salt aggregation test of ammonium sulphate. The hydrophobic character of strains exposed to 1/2 to 1/8 minimal inhibitory concentration (MIC) of amikacin and 1/2 to 1/16 MIC of ciprofloxacin was altered to a hydrophilic state. Results of the SAT also correlated with these data. Moreover, comparisons were made between the number of bacteria attached to the epithelial cells before and after exposure to 1/2, 1/4 and 1/8 MIC of antibiotics. The greatest loss of adherence capability occurred at 1/2 MIC of ciprofloxacin. In conclusion, antibiotics are often present at sub-MICs and may still be effective in reducing bacterial virulence by interfering with bacterial cell functions.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17382520     DOI: 10.1016/j.ijantimicag.2007.01.007

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  13 in total

1.  Association study of multiple antibiotic resistance and virulence: a strategy to assess the extent of risk posed by bacterial population in aquatic environment.

Authors:  Santosh Kumar Singh; Roseleen Ekka; Mitali Mishra; Harapriya Mohapatra
Journal:  Environ Monit Assess       Date:  2017-06-07       Impact factor: 2.513

2.  Anti-Pseudomonas aeruginosa IgY Antibodies Induce Specific Bacterial Aggregation and Internalization in Human Polymorphonuclear Neutrophils.

Authors:  K Thomsen; L Christophersen; T Bjarnsholt; P Ø Jensen; C Moser; N Høiby
Journal:  Infect Immun       Date:  2015-04-20       Impact factor: 3.441

Review 3.  A review on anti-adhesion therapies of bacterial diseases.

Authors:  Arezoo Asadi; Shabnam Razavi; Malihe Talebi; Mehrdad Gholami
Journal:  Infection       Date:  2018-10-01       Impact factor: 3.553

Review 4.  Targeting the bacteria-host interface: strategies in anti-adhesion therapy.

Authors:  Anne Marie Krachler; Kim Orth
Journal:  Virulence       Date:  2013-05-15       Impact factor: 5.882

5.  Effect of sub-minimum inhibitory concentrations of ciprofloxacin, amikacin and colistin on biofilm formation and virulence factors of Escherichia coli planktonic and biofilm forms isolated from human urine.

Authors:  Dorota Wojnicz; Dorota Tichaczek-Goska
Journal:  Braz J Microbiol       Date:  2013-05-31       Impact factor: 2.476

6.  Frequency distribution of virulence factors in uropathogenic Escherichia coli isolated from Kermanshah in 2011-2012.

Authors:  Parviz Mohajeri; Hosna Khademi; Roya Ebrahimi; Abbas Farahani; Mansour Rezaei
Journal:  Int J Appl Basic Med Res       Date:  2014-07

7.  Effect of asiatic and ursolic acids on morphology, hydrophobicity, and adhesion of UPECs to uroepithelial cells.

Authors:  Wojnicz Dorota; Kicia Marta; Tichaczek-Goska Dorota
Journal:  Folia Microbiol (Praha)       Date:  2012-11-07       Impact factor: 2.099

8.  Subinhibitory concentrations of triclosan promote Streptococcus mutans biofilm formation and adherence to oral epithelial cells.

Authors:  Telma Blanca Lombardo Bedran; Louis Grignon; Denise Palomari Spolidorio; Daniel Grenier
Journal:  PLoS One       Date:  2014-02-13       Impact factor: 3.240

9.  Genotyping of ESBL Producing Uropathogenic Escherichia coli in West of Iran.

Authors:  Parviz Mohajeri; Gita Darfarin; Abbas Farahani
Journal:  Int J Microbiol       Date:  2014-04-15

10.  Synergy and Mode of Action of Ceftazidime plus Quercetin or Luteolin on Streptococcus pyogenes.

Authors:  Supatcharee Siriwong; Kanjana Thumanu; Tanaporn Hengpratom; Griangsak Eumkeb
Journal:  Evid Based Complement Alternat Med       Date:  2015-10-21       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.